Medtronic Voluntary Response To MIS Data Integrity Problems Averts AIP
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's voluntary actions to ensure data integrity in premarket submissions from its Micro Interventional Systems unit appears to have helped avert imposition of FDA's application integrity policy.
You may also be interested in...
MIS Execs Allegedly Defrauded FDA During Acquisition Talks With Medtronic
While Micro Interventional Systems was in discussions with Medtronic about a possible acquisition in November 1995, two executives at the Sunnyvale, California-based firm allegedly were falsifying data in various 510(k) submissions to FDA in an apparent attempt to impress Medtronic with the breadth of MIS' neurovascular product pipeline.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.